

## Product datasheet for TL511291V

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

# **Ppara Mouse shRNA Lentiviral Particle (Locus ID 19013)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** Ppara Mouse shRNA Lentiviral Particle (Locus ID 19013)

**Locus ID:** 19013

Synonyms: 4933429D07Rik; AW742785; Nr1c1; Ppar; PPAR-alpha; PPARalpha

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

**Components:** Ppara - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: <u>BC016892</u>, <u>NM 001113418</u>, <u>NM 011144</u>, <u>NM 001113418.1</u>, <u>NM 011144.1</u>, <u>NM 011144.2</u>,

NM 011144.3, NM 011144.4, NM 011144.5, NM 011144.6

UniProt ID: P23204

Summary: Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the

endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC).

Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for

peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to

metabolic pathways regulated by PER2.[UniProtKB/Swiss-Prot Function]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







### **Performance Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).